#rimidi

[otiskeene]

Senseonics Partners With Rimidi To Develop Innovative Diabetes Solution

Senseonics Holdings, Inc. (NYSE American: SENS) and Rimidi are teaming up to create the Eversense Remote Patient Monitoring (RPM) Program, which will focus on improving diabetes care using new technology. Rimidi, known for its clinical management platform, wants to make managing chronic diseases, especially diabetes, easier for patients.

The partnership will combine Eversense glucose data with Rimidi's clinical management platform, which is used by health systems, health plans, and doctor's offices. This will work with Medicare's remote patient monitoring telehealth programs and fit into existing Electronic Health Record (EHR) systems. The goal is to improve care quality, streamline workflows, engage patients, and help with clinical decisions.

The Eversense CGM + RPM solution, with Rimidi's help, will securely send patient glucose data to popular EHR systems. This will give healthcare providers a better view of glucose trends, frequency of high or low events, and time spent in the target range. With this information, providers can work with patients to improve their lifestyle and therapy choices, leading to better diabetes management, lower costs, and better outcomes.

Tim Goodnow, PhD, President and CEO of Senseonics, explained that the Eversense RPM Program is part of their plan to combine long-term CGM technology with advanced analytics and personalized health services for a complete diabetes solution. This program aims to give providers the data they need to improve care between visits, where most diabetes management happens. The Eversense CGM+RPM solution, along with Rimidi's platform, aims to set Eversense apart from other CGM makers by offering a complete solution.

Read More - https://www.techdogs.com/tech-news/business-wire/senseonics-partners-with-rimidi-to-develop-innovative-diabetes-solution

[findyourrimidi]

The happiest of birthdays to RIMIDI’s first born who has turned the big 18 today, Laii 🥳 (at 𝑯𝒂𝒑𝒑𝒚 𝑩𝒊𝒓𝒕𝒉𝒅𝒂𝒚) https://www.instagram.com/p/CkdshZbLkCP/?igshid=NGJjMDIxMWI=

[biotech-news-feed]

Senseonics (NYSE:SENS) announced today that it entered into a strategic partnership with Rimidi to develop a remote patient monitoring program. Rimidi develops clinical management platforms for optimizing workflows, enhance patient experiences and h #BioTech #science

[ghosthoodie]

[freemindtech]

Rimidi Achieves 2021 Net Promoter Score (NPS) of 70, Putting Company in the 100th Percentile for the Software industry

Rimidi Achieves 2021 Net Promoter Score (NPS) of 70, Putting Company in the 100th Percentile for the Software industry

This year COVID-19 has continued to bring challenges to hospitals and health systems. We are dedicated to delivering exceptional service and user experience to our customers and have worked diligently to help them address many challenges that have arisen as a result of the pandemic. ATLANTA (PRWEB) October 28, 2021 Rimidi, a leading clinical management platform designed to optimize clinical…

[giankamoverona]

#unattenzioneinpiú La Salvia, non serve solo per insaporire le le nostre pietanze, ma può fungere da rimidi in tantissime occasioni... https://www.instagram.com/p/CKT8kNknnn2/?igshid=rxqv3pa39lsg

[kunalcmi]

SMART INSULIN PEN MARKET ANALYSIS (2019-2027)

Smart Insulin Pen Market – Insights

Smart insulin pens are Bluetooth-enabled wireless devices that are used for insulin delivery. These pens can track critical data such as time, date, and amount of insulin administered by a patient in order to offer efficient diabetes management.

 Statistics:

The global smart insulin pen market is estimated to account for US$ 5.3 Mn in terms of value by the end of 2027.

 Global Smart Insulin Pen Market: Drivers

Increasing prevalence of diabetes is a major factor boosting growth of the global smart insulin pen market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

Moreover, concerns about needle-stick injuries is also expected to aid in growth of the market. Needle stick injuries with diabetes injection needles and lancing devices are a key concern for diabetics. Insulin syringe needle stick injuries is a percutaneous wound injury caused by the needle tips and can occur while using, handling, disassembling, or disposing needles and syringes.

Europe region held dominant position in the global smart insulin pen market in 2019, accounting for 58.2% share in terms of value, followed by Asia Pacific.

 Figure 1. Global Smart Insulin Pen Market Share (%), by Region, 2019

 Global Smart Insulin Pen Market: Restraints

Limited adoption of smart insulin delivery systems, especially in emerging economies, is expected to hamper growth of the global smart insulin pen market. This is attributed to the high cost of the smart insulin pen, limited reimbursement, and less awareness among the diabetic patients regarding the technology.

Moreover, availability of substitute products such as painless smart insulin patches is also expected to hinder growth of the market. Wearable insulin patches allow more discrete insulin dosing throughout the day providing injection-free delivery of insulin whenever needed thus keeping the blood sugar levels in check.  The patch works faster compared to an insulin pen, is easy to use, and made up of biocompatible material.

 Global Smart Insulin Pen Market: Opportunities

Players in the global smart insulin pen market can focus on adopting online distribution channels, owing to increasing number of internet users and high adoption of online shopping. For instance, according to China Internet Network Information Center (CNNIC) (2018), 802 million people in China are now actively using the internet, which accounts for 57.7% of the population.

Moreover, high prevalence of diabetes in emerging regions is also expected to aid in growth of the market. For instance, according to International Diabetes Federation, the prevalence of type 2 diabetes in Asia Pacific is expected increase over 150% between 2000 and 2035.

Type 2 Diabetes segment in the global smart insulin pen market was valued at US$ 1.2 Mn in 2019 and is expected to reach US$ 4.4 Mn by 2027 at a CAGR of 18.9% during the forecast period.

Request Sample Free Copy of Report here: https://www.coherentmarketinsights.com/insight/request-sample/3436

Download PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/3436

 Market Trends/Key Takeaways

 Start-ups in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Bigfoot Biomedical, a diabetes startup focused on automated insulin delivery via connected insulin pens, initiated its Series C round with an initial tranche of US$ 45 million.

Players in the market are also focused on bringing connected insulin data into the clinical workflow. For instance, in June 2019, Companion Medical partnered with Rimidi, a cloud-based connected care software solution provider, to enable clinicians to analyze real-time insulin dosage integrated with data from connected glucometers and CGMs to remotely refine dosing decisions, all while working within the existing clinical workflow.

 Global Smart Insulin Pen Market: Competitive Landscape

Major players operating in the global smart insulin pen market include, Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Novo Nordisk, and Companion Medical Inc.

 Global Smart Insulin Pen Market: Key Developments

Players in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Companion Medical, Inc. entered into a loan and security agreement for up to US$ 27.5 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

  About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Explore CMI Services here

Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Source: https://www.coherentmarketinsights.com/market-insight/smart-insulin-pen-market-3436

[findyourrimidi]

Lyric Video for Latest New Single #Surreal

"SURREAL" SINGLE RELEASE FROM THE UPCOMING AND UNRELEASED ALBUM BY RIMIDI OUT NOW!!! VISIT WWW.FINDYOURRIMIDI.COM TO DOWNLOAD!!!

Surreal (New Single) Available NOW!!

Download: http://findyourrimidi.com

Follow RIMIDI on:

Facebook: https://bit.ly/RIMIDIFacebook

Twitter: https://bit.ly/RIMIDITwitter

Instagram: https://bit.ly/RIMIDIInstagram

Spotify: https://bit.ly/RIMIDISpotify

YouTube: https://bit.ly/RIMIDIYouTube

SoundCloud: https://bit.ly/RIMIDISoundCloud

Tumblr: https://bit.ly/RIMIDITumblr

[adwaitcoherent]

By 2027, Smart Insulin Pen Market To Surpass US$ 5.3 Mn

From 2019 to 2017, Smart Insulin Pen Market To show exponential growth of CAGR of 14.5%

Request for Sample PDF Copy:

https://www.coherentmarketinsights.com/insight/request-pdf/3436

Figure 1. Global Smart Insulin Pen Market Share (%), by Region, 2019

Description:

Smart insulin pens are Bluetooth-enabled wireless devices that are used for insulin delivery. These pens can track critical data such as time, date, and amount of insulin administered by a patient in order to offer efficient diabetes management.

 Statistics:

The global smart insulin pen market is estimated to account for US$ 5.3 Mn in terms of value by the end of 2027.

 Global Smart Insulin Pen Market: Drivers

 Increasing prevalence of diabetes is a major factor boosting growth of the global smart insulin pen market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

 Moreover, concerns about needle-stick injuries is also expected to aid in growth of the market. Needle stick injuries with diabetes injection needles and lancing devices are a key concern for diabetics. Insulin syringe needle stick injuries is a percutaneous wound injury caused by the needle tips and can occur while using, handling, disassembling, or disposing needles and syringes.

 Europe region held dominant position in the global smart insulin pen market in 2019, accounting for 58.2% share in terms of value, followed by Asia Pacific.

   Smart Insulin Pen  | Coherent Market Insights

 Global Smart Insulin Pen Market: Restraints

 Limited adoption of smart insulin delivery systems, especially in emerging economies, is expected to hamper growth of the global smart insulin pen market. This is attributed to the high cost of the smart insulin pen, limited reimbursement, and less awareness among the diabetic patients regarding the technology.

 Moreover, availability of substitute products such as painless smart insulin patches is also expected to hinder growth of the market. Wearable insulin patches allow more discrete insulin dosing throughout the day providing injection-free delivery of insulin whenever needed thus keeping the blood sugar levels in check.  The patch works faster compared to an insulin pen, is easy to use, and made up of biocompatible material.

 Global Smart Insulin Pen Market: Opportunities

 Players in the global smart insulin pen market can focus on adopting online distribution channels, owing to increasing number of internet users and high adoption of online shopping. For instance, according to China Internet Network Information Center (CNNIC) (2018), 802 million people in China are now actively using the internet, which accounts for 57.7% of the population.

 Moreover, high prevalence of diabetes in emerging regions is also expected to aid in growth of the market. For instance, according to International Diabetes Federation, the prevalence of type 2 diabetes in Asia Pacific is expected increase over 150% between 2000 and 2035.

 Type 2 Diabetes segment in the global smart insulin pen market was valued at US$ 1.2 Mn in 2019 and is expected to reach US$ 4.4 Mn by 2027 at a CAGR of 18.9% during the forecast period.

 Market Trends/Key Takeaways

 Start-ups in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Bigfoot Biomedical, a diabetes startup focused on automated insulin delivery via connected insulin pens, initiated its Series C round with an initial tranche of US$ 45 million.

 Players in the market are also focused on bringing connected insulin data into the clinical workflow. For instance, in June 2019, Companion Medical partnered with Rimidi, a cloud-based connected care software solution provider, to enable clinicians to analyze real-time insulin dosage integrated with data from connected glucometers and CGMs to remotely refine dosing decisions, all while working within the existing clinical workflow.

 Global Smart Insulin Pen Market: Competitive Landscape

 Major players operating in the global smart insulin pen market include, Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Novo Nordisk, and Companion Medical Inc.

 Global Smart Insulin Pen Market: Key Developments

 Players in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Companion Medical, Inc. entered into a loan and security agreement for up to US$ 27.5 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We do offer wide range of services such as Industry analysis, Consulting services, Market Intelligence, Customized research services and much more. We have expertise in many fields such as healthcare, chemicals and materials, Automation, semiconductors, electronics, energy, food and beverage, packaging and many more. Visit our website to know more.

Buy Report Here:

https://www.coherentmarketinsights.com/insight/buy-now/3436

Contact Us: Mr. Shah Coherent Market Insights 1001 4th Ave.  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[meghannchilcott]

Rimidi Launches COVID-19 Screening App to Identify At-Risk Patients & Limit Exposure https://hitconsultant.net/2020/03/06/rimidi-launches-ehr-integrated-covid-19-screening-app/

[pharmaphorumuk]

Novo Nordisk announces obesity digital health tie-up with Noom

Denmark’s Novo Nordisk has announced a tie-up with digital health firm Noom, focusing on helping people with obesity lose weight and keep it off.

The weight management and education initiative follows a successful eight-month pilot combined Noom’s behaviour change programmes with Novo’s expertise in chronic diseases.

Noom’s approach is to understand individual motivations and obstacles using cutting-edge technology, including artificial intelligence and behavioural coaching by more than 1,000 personal health coaches.

It also uses data and wellness insights to guide people towards sustainable change.

Novo Nordisk is one of several companies in obesity and diabetes that is using digital technology to help tackle the conditions.

Last month Novo reached an agreement with digital device firm Medtronic to allow dosing data from the Danish pharma’s insulin pens to be shared with the US firm’s glucose monitoring devices.

Another example is Eli Lilly – in January, the company announced an expansion of a digital collaboration with Livongo, focusing on using real world studies to develop new insights into diabetes.

This built on a 2017 partnership with Rimidi, which will provide the software underpinning Eli Lilly’s digital diabetes management programme.

Novo Nordisk is also developing its GLP-1 class drug semaglutide as a treatment for obesity, after successfully bringing it to market as a weekly injection, and as a daily pill, in type 2 diabetes to help manage blood sugar levels.

Camilla Sylvest, Novo Nordisk executive vice president, commercial strategy and corporate affairs, said: “We are passionate about improving the lives of people with obesity and finding new solutions to support respectful and complete care, which includes lifestyle change and medical management.”

Saeju Jeong, CEO and co-founder of Noom, added: “Sustainable change can’t happen in a vacuum, and those living with obesity who want to manage their weight are in need of personalised human coaching to help them change their habits, so they can lose weight for good.”

The post Novo Nordisk announces obesity digital health tie-up with Noom appeared first on .

from https://pharmaphorum.com/news/novo-nordisk-announces-obesity-digital-health-tie-up-with-noom/

[freemindtech]

Rimidi Announces Official Launch of EHR-Integrated Patient Reported Outcomes Tool, Survé

Rimidi Announces Official Launch of EHR-Integrated Patient Reported Outcomes Tool, Survé

Looking forward, these self-reported outcomes must become part of the comprehensive medical record for each patient and be applied and implemented across clinical use cases to drive shared decision-making and to ultimately lead to greater health outcomes. ATLANTA (PRWEB) September 30, 2021 Rimidi, a leading clinical management platform designed to optimize clinical workflows, today announced…

[technicallyyoungkitten]

Smart Insulin Pen Market Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Smart insulin pens are Bluetooth-enabled wireless devices that are used for insulin delivery. These pens can track critical data such as time, date, and amount of insulin administered by a patient in order to offer efficient diabetes management.The global smart insulin pen market is estimated to account for US$ 5.3 Mn in terms of value by the end of 2027.

Browse Summary of the Research Report- https://www.coherentmarketinsights.com/market-insight/smart-insulin-pen-market-3436

Increasing prevalence of diabetes is a major factor boosting growth of the global smart insulin pen market over the forecast period. For instance, according to the study, ‘Global Prevalence of Type 2 Diabetes over the Next Ten Years (2018-2028)’, published by the American Diabetes Association, 500 million people worldwide suffered from type 2 diabetes in 2018.

Moreover, concerns about needle-stick injuries is also expected to aid in growth of the market. Needle stick injuries with diabetes injection needles and lancing devices are a key concern for diabetics. Insulin syringe needle stick injuries is a percutaneous wound injury caused by the needle tips and can occur while using, handling, disassembling, or disposing needles and syringes.Europe region held dominant position in the global smart insulin pen market in 2019, accounting for 58.2% share in terms of value, followed by Asia Pacific.

Limited adoption of smart insulin delivery systems, especially in emerging economies, is expected to hamper growth of the global smart insulin pen market. This is attributed to the high cost of the smart insulin pen, limited reimbursement, and less awareness among the diabetic patients regarding the technology.Moreover, availability of substitute products such as painless smart insulin patches is also expected to hinder growth of the market. Wearable insulin patches allow more discrete insulin dosing throughout the day providing injection-free delivery of insulin whenever needed thus keeping the blood sugar levels in check.  The patch works faster compared to an insulin pen, is easy to use, and made up of biocompatible material.

Players in the global smart insulin pen market can focus on adopting online distribution channels, owing to increasing number of internet users and high adoption of online shopping. For instance, according to China Internet Network Information Center (CNNIC) (2018), 802 million people in China are now actively using the internet, which accounts for 57.7% of the population.Moreover, high prevalence of diabetes in emerging regions is also expected to aid in growth of the market. For instance, according to International Diabetes Federation, the prevalence of type 2 diabetes in Asia Pacific is expected increase over 150% between 2000 and 2035.

Type 2 Diabetes segment in the global smart insulin pen market was valued at US$ 1.2 Mn in 2019 and is expected to reach US$ 4.4 Mn by 2027 at a CAGR of 18.9% during the forecast period.Start-ups in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Bigfoot Biomedical, a diabetes startup focused on automated insulin delivery via connected insulin pens, initiated its Series C round with an initial tranche of US$ 45 million.

Players in the market are also focused on bringing connected insulin data into the clinical workflow. For instance, in June 2019, Companion Medical partnered with Rimidi, a cloud-based connected care software solution provider, to enable clinicians to analyze real-time insulin dosage integrated with data from connected glucometers and CGMs to remotely refine dosing decisions, all while working within the existing clinical workflow.

Major players operating in the global smart insulin pen market include, Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Novo Nordisk, and Companion Medical Inc.Players in the market are focused on raising funds for expanding their product portfolio. For instance, in January 2020, Companion Medical, Inc. entered into a loan and security agreement for up to US$ 27.5 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.

Request A Sample Copy - https://www.coherentmarketinsights.com/insight/request-sample/3436

Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com *****************************************************************************

[ketan-wagh121-blog]

United States Smart Insulin Pen Market 2019 - Industry Analysis, Size, Share, Strategies and Forecast to 2026

United States Smart Insulin Pen Market

Latest Report On 2019 Smart Insulin Pen Market United States Analysis & 2026 Forecast Research Study

The lack of devices that could aid in managing of diabetes is projected to spur the integration of technology such as Bluetooth, apps and cloud technology among others is anticipated to bolster the smart insulin pen injectors market around the world. The conventional glucometer’s integration with insulin pens that are broadly used than insulin pumps is expected to augment the convenience factor and thus translate to an incremental growth pace for the smart insulin pen market. Moreover, the availability of scanning via apps and real-time alerts are estimated to offer life-altering technology to individuals living with diabetes. Recently, Biocorp, manufacturer of an Internet-connected cap for insulin pen injectors that can routinely convey dosage data to a mobile app, has entered into private discussions for usage of the device in Sanofi’s diabetes care program. The smart sensor cap, Mallya, is an original connected device for injection pens that have been assessed to touch the accuracy conditions for a CE Class IIb, medical device label by European regulators. Biocorp also added that it would obtain a preliminary sum of €4 million from Sanofi to back-related development activities under the private negotiation, which is the initial step toward a partnership with Sanofi. The central players shaping the smart insulin pen market are Companion Medical, Diabnext, Digital Medics Ptd Ltd., Emperra GmbH E-Health Technologies and Diamesco Co., Ltd. to name a few.

The United States smart insulin pen market is expected to witness a CAGR of more than 35% to reach market value of around US$ 392 Million by 2026.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/3997660-smart-insulin-pen-market-outlook-2026-united-states

The surge in cases of diabetes is a major driving force for the expansion of the smart insulin pen market globally. The patients who have diabetes have become more hands-on in terms of it’s management. A better understanding of treatment options such as smart insulin pens is expected to rise in the coming period. Moreover, the availability of better product options is expected to reinforce the development of the market. The insulin pens available these days are “connected” insulin pens which are refillable and function with insulin cartridges effortlessly. The increased rate of development in the market is expected to push cost benefits towards the end-users of the smart insulin pen market. The use of smart insulin pens is estimated to promote a reduction in environmental pollution from insulin containers as smart pens are refillable.

The ability to pre-load doses in smart insulin pens is significantly motivating the overall demand increasingly. Also, the collaboration between industry giants and specialty firms in the market are promoting further expansion of the market. Case in point is that of Rimidi and Companion Medical who announced a first-of-its-kind collaboration to improve data visualization for clinicians handling high-risk patients with diabetes who are being administered insulin therapy. The association fits in Companion Medical’s connected device, InPen, the original and lone FDA-cleared, smart insulin pen matched with an integrated diabetes managing app, into Rimidi’s platform by running insulin dosing data from the InPen over the cloud. The collaborations of this type are utilizing devices such as connected glucometers with very optimistic effects on diabetes results showing improvements in a lesser timeframe. The need to implicitly hasten the trial and error process of recognizing the optimum dose for each patient while driving down costs is expected to encourage the smart insulin pen market further.

For Detailed Reading Please visit WiseGuy Reports @ https://www.wiseguyreports.com/reports/3997660-smart-insulin-pen-market-outlook-2026-united-states

For more information or any query mail at sales@wiseguyreports.com

About Us Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

[brentrogers]

Rimidi Unveils New App To Accelerate Patient Screenings for COVID-19

This article is copyrighted strictly for Electronic Health Reporter. Illegal copying is prohibited.

Rimidi, a cloud-based software platform, announced the launch of its patient-reported outcomes survey app to help limit the spread of COVID-19 in healthcare settings. Currently, the app is in expedited beta testing by select U.S. […]

The article Rimidi Unveils New App To Accelerate Patient Screenings for COVID-19 appeared first on electronichealthreporter.com.

Rimidi Unveils New App To Accelerate Patient Screenings for COVID-19 syndicated from